Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 20
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
J Cell Sci ; 136(18)2023 09 15.
Artículo en Inglés | MEDLINE | ID: mdl-37642648

RESUMEN

Myelinating Schwann cell (SC)-dorsal root ganglion (DRG) neuron cocultures are an important technique for understanding cell-cell signalling and interactions during peripheral nervous system (PNS) myelination, injury, and regeneration. Although methods using rat SCs and neurons or mouse DRG explants are commonplace, there are no established protocols for compartmentalised myelinating cocultures with dissociated mouse cells. There consequently is a need for a coculture protocol that allows separate genetic manipulation of mouse SCs or neurons, or use of cells from different transgenic animals to complement in vivo mouse experiments. However, inducing myelination of dissociated mouse SCs in culture is challenging. Here, we describe a new method to coculture dissociated mouse SCs and DRG neurons in microfluidic chambers and induce robust myelination. Cocultures can be axotomised to study injury and used for drug treatments, and cells can be lentivirally transduced for live imaging. We used this model to investigate axon degeneration after traumatic axotomy and find that SCs, irrespective of myelination status, are axo-protective. At later timepoints after injury, live imaging of cocultures shows that SCs break up, ingest and clear axonal debris.


Asunto(s)
Neuronas , Células de Schwann , Animales , Ratones , Ratas , Técnicas de Cocultivo , Axones , Animales Modificados Genéticamente
2.
Lancet ; 398(10306): 1147-1156, 2021 09 25.
Artículo en Inglés | MEDLINE | ID: mdl-34370972

RESUMEN

BACKGROUND: A new syndrome of vaccine-induced immune thrombotic thrombocytopenia (VITT) has emerged as a rare side-effect of vaccination against COVID-19. Cerebral venous thrombosis is the most common manifestation of this syndrome but, to our knowledge, has not previously been described in detail. We aimed to document the features of post-vaccination cerebral venous thrombosis with and without VITT and to assess whether VITT is associated with poorer outcomes. METHODS: For this multicentre cohort study, clinicians were asked to submit all cases in which COVID-19 vaccination preceded the onset of cerebral venous thrombosis, regardless of the type of vaccine, interval between vaccine and onset of cerebral venous thrombosis symptoms, or blood test results. We collected clinical characteristics, laboratory results (including the results of tests for anti-platelet factor 4 antibodies where available), and radiological features at hospital admission of patients with cerebral venous thrombosis after vaccination against COVID-19, with no exclusion criteria. We defined cerebral venous thrombosis cases as VITT-associated if the lowest platelet count recorded during admission was below 150 × 109 per L and, if the D-dimer was measured, the highest value recorded was greater than 2000 µg/L. We compared the VITT and non-VITT groups for the proportion of patients who had died or were dependent on others to help them with their activities of daily living (modified Rankin score 3-6) at the end of hospital admission (the primary outcome of the study). The VITT group were also compared with a large cohort of patients with cerebral venous thrombosis described in the International Study on Cerebral Vein and Dural Sinus Thrombosis. FINDINGS: Between April 1 and May 20, 2021, we received data on 99 patients from collaborators in 43 hospitals across the UK. Four patients were excluded because they did not have definitive evidence of cerebral venous thrombosis on imaging. Of the remaining 95 patients, 70 had VITT and 25 did not. The median age of the VITT group (47 years, IQR 32-55) was lower than in the non-VITT group (57 years; 41-62; p=0·0045). Patients with VITT-associated cerebral venous thrombosis had more intracranial veins thrombosed (median three, IQR 2-4) than non-VITT patients (two, 2-3; p=0·041) and more frequently had extracranial thrombosis (31 [44%] of 70 patients) compared with non-VITT patients (one [4%] of 25 patients; p=0·0003). The primary outcome of death or dependency occurred more frequently in patients with VITT-associated cerebral venous thrombosis (33 [47%] of 70 patients) compared with the non-VITT control group (four [16%] of 25 patients; p=0·0061). This adverse outcome was less frequent in patients with VITT who received non-heparin anticoagulants (18 [36%] of 50 patients) compared with those who did not (15 [75%] of 20 patients; p=0·0031), and in those who received intravenous immunoglobulin (22 [40%] of 55 patients) compared with those who did not (11 [73%] of 15 patients; p=0·022). INTERPRETATION: Cerebral venous thrombosis is more severe in the context of VITT. Non-heparin anticoagulants and immunoglobulin treatment might improve outcomes of VITT-associated cerebral venous thrombosis. Since existing criteria excluded some patients with otherwise typical VITT-associated cerebral venous thrombosis, we propose new diagnostic criteria that are more appropriate. FUNDING: None.


Asunto(s)
Vacunas contra la COVID-19/efectos adversos , Trombosis Intracraneal/epidemiología , Púrpura Trombocitopénica Idiopática/epidemiología , Vacunación/efectos adversos , Adulto , Vacunas contra la COVID-19/inmunología , Estudios de Cohortes , Femenino , Productos de Degradación de Fibrina-Fibrinógeno , Humanos , Trombosis Intracraneal/tratamiento farmacológico , Trombosis Intracraneal/mortalidad , Masculino , Persona de Mediana Edad , Recuento de Plaquetas , Púrpura Trombocitopénica Idiopática/tratamiento farmacológico , SARS-CoV-2 , Reino Unido/epidemiología , Trombosis de la Vena/tratamiento farmacológico , Trombosis de la Vena/epidemiología
3.
Glia ; 68(8): 1568-1583, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-31958184

RESUMEN

DNA methylation is one of many epigenetic marks, which directly modifies base residues, usually cytosines, in a multiple-step cycle. It has been linked to the regulation of gene expression and alternative splicing in several cell types, including during cell lineage specification and differentiation processes. DNA methylation changes have also been observed during aging, and aberrant methylation patterns have been reported in several neurological diseases. We here review the role of DNA methylation in Schwann cells and oligodendrocytes, the myelin-forming glia of the peripheral and central nervous systems, respectively. We first address how methylation and demethylation are regulating myelinating cells' differentiation during development and repair. We then mention how DNA methylation dysregulation in diseases and cancers could explain their pathogenesis by directly influencing myelinating cells' proliferation and differentiation capacities.


Asunto(s)
Vaina de Mielina/metabolismo , Neuroglía/metabolismo , Oligodendroglía/metabolismo , Células de Schwann/metabolismo , Animales , Diferenciación Celular/fisiología , Linaje de la Célula/fisiología , Humanos
4.
Glia ; 67(3): 421-437, 2019 03.
Artículo en Inglés | MEDLINE | ID: mdl-30632639

RESUMEN

Schwann cells respond to nerve injury by cellular reprogramming that generates cells specialized for promoting regeneration and repair. These repair cells clear redundant myelin, attract macrophages, support survival of damaged neurons, encourage axonal growth, and guide axons back to their targets. There are interesting parallels between this response and that found in other tissues. At the cellular level, many other tissues also react to injury by cellular reprogramming, generating cells specialized to promote tissue homeostasis and repair. And at the molecular level, a common feature possessed by Schwann cells and many other cells is the injury-induced activation of genes associated with epithelial-mesenchymal transitions and stemness, differentiation states that are linked to cellular plasticity and that help injury-induced tissue remodeling. The number of signaling systems regulating Schwann cell plasticity is rapidly increasing. Importantly, this includes mechanisms that are crucial for the generation of functional repair Schwann cells and nerve regeneration, although they have no or a minor role elsewhere in the Schwann cell lineage. This encourages the view that selective tools can be developed to control these particular cells, amplify their repair supportive functions and prevent their deterioration. In this review, we discuss the emerging similarities between the injury response seen in nerves and in other tissues and survey the transcription factors, epigenetic mechanisms, and signaling cascades that control repair Schwann cells, with emphasis on systems that selectively regulate the Schwann cell injury response.


Asunto(s)
Vaina de Mielina/fisiología , Regeneración Nerviosa/fisiología , Plasticidad Neuronal/fisiología , Células de Schwann/fisiología , Animales , Axones/fisiología , Modelos Animales de Enfermedad , Transición Epitelial-Mesenquimal/fisiología
5.
Front Cell Neurosci ; 17: 1158388, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37091921

RESUMEN

Since SARM1 mutations have been identified in human neurological disease, SARM1 inhibition has become an attractive therapeutic strategy to preserve axons in a variety of disorders of the peripheral (PNS) and central nervous system (CNS). While SARM1 has been extensively studied in neurons, it remains unknown whether SARM1 is present and functional in myelinating glia? This is an important question to address. Firstly, to identify whether SARM1 dysfunction in other cell types in the nervous system may contribute to neuropathology in SARM1 dependent diseases? Secondly, to ascertain whether therapies altering SARM1 function may have unintended deleterious impacts on PNS or CNS myelination? Surprisingly, we find that oligodendrocytes express sarm1 mRNA in the zebrafish spinal cord and that SARM1 protein is readily detectable in rodent oligodendrocytes in vitro and in vivo. Furthermore, activation of endogenous SARM1 in cultured oligodendrocytes induces rapid cell death. In contrast, in peripheral glia, SARM1 protein is not detectable in Schwann cells and satellite glia in vivo and sarm1/Sarm1 mRNA is detected at very low levels in Schwann cells, in vivo, in zebrafish and mouse. Application of specific SARM1 activators to cultured mouse Schwann cells does not induce cell death and nicotinamide adenine dinucleotide (NAD) levels remain unaltered suggesting Schwann cells likely contain no functionally relevant levels of SARM1. Finally, we address the question of whether SARM1 is required for myelination or myelin maintenance. In the zebrafish and mouse PNS and CNS, we show that SARM1 is not required for initiation of myelination and myelin sheath maintenance is unaffected in the adult mouse nervous system. Thus, strategies to inhibit SARM1 function to treat neurological disease are unlikely to perturb myelination in humans.

6.
Cell Metab ; 35(12): 2136-2152.e9, 2023 12 05.
Artículo en Inglés | MEDLINE | ID: mdl-37989315

RESUMEN

The peripheral nervous system harbors a remarkable potential to regenerate after acute nerve trauma. Full functional recovery, however, is rare and critically depends on peripheral nerve Schwann cells that orchestrate breakdown and resynthesis of myelin and, at the same time, support axonal regrowth. How Schwann cells meet the high metabolic demand required for nerve repair remains poorly understood. We here report that nerve injury induces adipocyte to glial signaling and identify the adipokine leptin as an upstream regulator of glial metabolic adaptation in regeneration. Signal integration by leptin receptors in Schwann cells ensures efficient peripheral nerve repair by adjusting injury-specific catabolic processes in regenerating nerves, including myelin autophagy and mitochondrial respiration. Our findings propose a model according to which acute nerve injury triggers a therapeutically targetable intercellular crosstalk that modulates glial metabolism to provide sufficient energy for successful nerve repair.


Asunto(s)
Vaina de Mielina , Nervios Periféricos , Vaina de Mielina/metabolismo , Neuroglía , Células de Schwann/metabolismo , Regeneración Nerviosa/fisiología
7.
Elife ; 112022 01 25.
Artículo en Inglés | MEDLINE | ID: mdl-35076395

RESUMEN

The class IIa histone deacetylases (HDACs) have pivotal roles in the development of different tissues. Of this family, Schwann cells express Hdac4, 5, and 7 but not Hdac9. Here, we show that a transcription factor regulated genetic compensatory mechanism within this family of proteins, blocks negative regulators of myelination ensuring peripheral nerve developmental myelination and remyelination after injury. Thus, when Hdac4 and 5 are knocked-out from Schwann cells in mice, a JUN-dependent mechanism induces the compensatory overexpression of Hdac7 permitting, although with a delay, the formation of the myelin sheath. When Hdac4, 5, and 7 are simultaneously removed, the myocyte-specific enhancer-factor d (MEF2D) binds to the promoter and induces the de novo expression of Hdac9, and although several melanocytic lineage genes are misexpressed and Remak bundle structure is disrupted, myelination proceeds after a long delay. Thus, our data unveil a finely tuned compensatory mechanism within the class IIa Hdac family, coordinated by distinct transcription factors, that guarantees the ability of Schwann cells to myelinate during development and remyelinate after nerve injury.


Asunto(s)
Regulación de la Expresión Génica/fisiología , Genes jun/genética , Histona Desacetilasas/genética , Nervios Periféricos/fisiología , Remielinización , Células de Schwann/metabolismo , Animales , Femenino , Histona Desacetilasas/metabolismo , Factores de Transcripción MEF2/genética , Factores de Transcripción MEF2/metabolismo , Masculino , Ratones
8.
Glia ; 59(5): 720-33, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21322058

RESUMEN

Genetically modified mice have been a major source of information about the molecular control of Schwann-cell myelin formation, and the role of ß-neuregulin 1 (NRG1) in this process in vivo. In vitro, on the other hand, Schwann cells from rats have been used in most analyses of the signaling pathways involved in myelination. To correlate more effectively in vivo and in vitro data, we used purified cultures of mouse Schwann cells in addition to rat Schwann cells to examine two important myelin-related signals, cyclic adenosine monophosphate (cAMP), and NRG1 and to determine whether they interact to control myelin differentiation. We find that in mouse Schwann cells, neither cAMP nor NRG1, when used separately, induced markers of myelin differentiation. When combined, however, they induced strong protein expression of the myelin markers, Krox-20 and P(0) . Importantly, the level of cAMP signaling was crucial in switching NRG1 from a proliferative signal to a myelin differentiation signal. Also in cultured rat Schwann cells, NRG1 promoted cAMP-induced Krox-20 and P(0) expression. Finally, we found that cAMP/NRG1-induced Schwann-cell differentiation required the activity of the cAMP response element binding family of transcription factors in both mouse and rat cells. These observations reconcile observations in vivo and on neuron-Schwann-cell cultures with studies on purified Schwann cells. They demonstrate unambiguously the promyelin effects of NRG1 in purified cells, and they show that the cAMP pathway determines whether NRG1 drives proliferation or induces myelin differentiation.


Asunto(s)
AMP Cíclico/metabolismo , Vaina de Mielina/metabolismo , Neurregulina-1/metabolismo , Células de Schwann/metabolismo , Análisis de Varianza , Animales , Western Blotting , Células Cultivadas , AMP Cíclico/farmacología , Inmunohistoquímica , Hibridación in Situ , Ratones , Proteína P0 de la Mielina/metabolismo , Vaina de Mielina/efectos de los fármacos , Neurregulina-1/farmacología , Ratas , Ratas Sprague-Dawley , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Células de Schwann/citología , Células de Schwann/efectos de los fármacos , Nervio Ciático/citología , Nervio Ciático/efectos de los fármacos , Nervio Ciático/metabolismo , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología
9.
Neurotherapeutics ; 18(4): 2200-2221, 2021 10.
Artículo en Inglés | MEDLINE | ID: mdl-34595734

RESUMEN

Since Waller and Cajal in the nineteenth and early twentieth centuries, laboratory traumatic peripheral nerve injury studies have provided great insight into cellular and molecular mechanisms governing axon degeneration and the responses of Schwann cells, the major glial cell type of peripheral nerves. It is now evident that pathways underlying injury-induced axon degeneration and the Schwann cell injury-specific state, the repair Schwann cell, are relevant to many inherited and acquired disorders of peripheral nerves. This review provides a timely update on the molecular understanding of axon degeneration and formation of the repair Schwann cell. We discuss how nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2) and sterile alpha TIR motif containing protein 1 (SARM1) are required for axon survival and degeneration, respectively, how transcription factor c-JUN is essential for the Schwann cell response to nerve injury and what each tells us about disease mechanisms and potential therapies. Human genetic association with NMNAT2 and SARM1 strongly suggests aberrant activation of programmed axon death in polyneuropathies and motor neuron disorders, respectively, and animal studies suggest wider involvement including in chemotherapy-induced and diabetic neuropathies. In repair Schwann cells, cJUN is aberrantly expressed in a wide variety of human acquired and inherited neuropathies. Animal models suggest it limits axon loss in both genetic and traumatic neuropathies, whereas in contrast, Schwann cell secreted Neuregulin-1 type 1 drives onion bulb pathology in CMT1A. Finally, we discuss opportunities for drug-based and gene therapies to prevent axon loss or manipulate the repair Schwann cell state to treat acquired and inherited neuropathies and neuronopathies.


Asunto(s)
Proteínas del Dominio Armadillo , Traumatismos de los Nervios Periféricos , Animales , Proteínas del Dominio Armadillo/genética , Proteínas del Dominio Armadillo/metabolismo , Axones/fisiología , Proteínas del Citoesqueleto/genética , Proteínas del Citoesqueleto/metabolismo , Traumatismos de los Nervios Periféricos/metabolismo , Traumatismos de los Nervios Periféricos/terapia
10.
Elife ; 102021 01 21.
Artículo en Inglés | MEDLINE | ID: mdl-33475496

RESUMEN

After nerve injury, myelin and Remak Schwann cells reprogram to repair cells specialized for regeneration. Normally providing strong regenerative support, these cells fail in aging animals, and during chronic denervation that results from slow axon growth. This impairs axonal regeneration and causes significant clinical problems. In mice, we find that repair cells express reduced c-Jun protein as regenerative support provided by these cells declines during aging and chronic denervation. In both cases, genetically restoring Schwann cell c-Jun levels restores regeneration to control levels. We identify potential gene candidates mediating this effect and implicate Shh in the control of Schwann cell c-Jun levels. This establishes that a common mechanism, reduced c-Jun in Schwann cells, regulates success and failure of nerve repair both during aging and chronic denervation. This provides a molecular framework for addressing important clinical problems, suggesting molecular pathways that can be targeted to promote repair in the PNS.


Asunto(s)
Envejecimiento , Regeneración Nerviosa , Proteínas Proto-Oncogénicas c-jun/genética , Células de Schwann/metabolismo , Animales , Femenino , Masculino , Ratones , Proteínas Proto-Oncogénicas c-jun/metabolismo
11.
Elife ; 102021 12 06.
Artículo en Inglés | MEDLINE | ID: mdl-34870595

RESUMEN

Axon loss underlies symptom onset and progression in many neurodegenerative disorders. Axon degeneration in injury and disease is promoted by activation of the NAD-consuming enzyme SARM1. Here, we report a novel activator of SARM1, a metabolite of the pesticide and neurotoxin vacor. Removal of SARM1 completely rescues mouse neurons from vacor-induced neuron and axon death in vitro and in vivo. We present the crystal structure of the Drosophila SARM1 regulatory domain complexed with this activator, the vacor metabolite VMN, which as the most potent activator yet known is likely to support drug development for human SARM1 and NMNAT2 disorders. This study indicates the mechanism of neurotoxicity and pesticide action by vacor, raises important questions about other pyridines in wider use today, provides important new tools for drug discovery, and demonstrates that removing SARM1 can robustly block programmed axon death induced by toxicity as well as genetic mutation.


Asunto(s)
Proteínas del Dominio Armadillo/genética , Axones/patología , Proteínas del Citoesqueleto/genética , Degeneración Nerviosa/fisiopatología , Neurotoxinas/farmacología , Compuestos de Fenilurea/farmacología , Animales , Proteínas del Dominio Armadillo/metabolismo , Axones/efectos de los fármacos , Proteínas del Citoesqueleto/metabolismo , Femenino , Masculino , Ratones , Degeneración Nerviosa/inducido químicamente , Rodenticidas/farmacología
12.
J Peripher Nerv Syst ; 13(2): 122-35, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18601657

RESUMEN

Immature Schwann cells found in perinatal rodent nerves are generated from Schwann cell precursors (SCPs) that originate from the neural crest. Immature Schwann cells generate the myelinating and non-myelinating Schwann cells of adult nerves. When axons degenerate following injury, Schwann cells demyelinate, proliferate and dedifferentiate to assume a molecular phenotype similar to that of immature cells, a process essential for successful nerve regeneration. Increasing evidence indicates that Schwann cell dedifferentiation involves activation of specific receptors, intracellular signalling pathways and transcription factors in a manner analogous to myelination. We have investigated the roles of Notch and the transcription factor c-Jun in development and after nerve transection. In vivo, Notch signalling regulates the transition from SCP to Schwann cell, times Schwann cell generation, controls Schwann cell proliferation and acts as a brake on myelination. Notch is elevated in injured nerves where it accelerates the rate of dedifferentiation. Likewise, the transcription factor c-Jun is required for Schwann cell proliferation and death and is down-regulated by Krox-20 on myelination. Forced expression of c-Jun in Schwann cells prevents myelination, and in injured nerves, c-Jun is required for appropriate dedifferentiation, the re-emergence of the immature Schwann cell state and nerve regeneration. Thus, both Notch and c-Jun are negative regulators of myelination. The growing realisation that myelination is subject to negative as well as positive controls and progress in molecular identification of negative regulators is likely to impact on our understanding of demyelinating disease and mechanisms that control nerve repair.


Asunto(s)
Desdiferenciación Celular/fisiología , Diferenciación Celular/fisiología , Desarrollo Embrionario/fisiología , Vaina de Mielina/fisiología , Células de Schwann/fisiología , Transducción de Señal/fisiología , Animales , Enfermedades Desmielinizantes/embriología , Enfermedades Desmielinizantes/metabolismo , Enfermedades Desmielinizantes/patología , Humanos , Vaina de Mielina/ultraestructura , Células de Schwann/ultraestructura
14.
Cell Rep ; 20(11): 2719-2734, 2017 Sep 12.
Artículo en Inglés | MEDLINE | ID: mdl-28903050

RESUMEN

Repair Schwann cells play a critical role in orchestrating nerve repair after injury, but the cellular and molecular processes that generate them are poorly understood. Here, we perform a combined whole-genome, coding and non-coding RNA and CpG methylation study following nerve injury. We show that genes involved in the epithelial-mesenchymal transition are enriched in repair cells, and we identify several long non-coding RNAs in Schwann cells. We demonstrate that the AP-1 transcription factor C-JUN regulates the expression of certain micro RNAs in repair Schwann cells, in particular miR-21 and miR-34. Surprisingly, unlike during development, changes in CpG methylation are limited in injury, restricted to specific locations, such as enhancer regions of Schwann cell-specific genes (e.g., Nedd4l), and close to local enrichment of AP-1 motifs. These genetic and epigenomic changes broaden our mechanistic understanding of the formation of repair Schwann cell during peripheral nervous system tissue repair.


Asunto(s)
Metilación de ADN/genética , Regeneración Nerviosa/genética , Traumatismos de los Nervios Periféricos/genética , ARN Largo no Codificante/genética , Células de Schwann/patología , Transcriptoma/genética , Animales , Islas de CpG/genética , Elementos de Facilitación Genéticos/genética , Transición Epitelial-Mesenquimal/genética , Regulación de la Expresión Génica , Ratones , MicroARNs/genética , MicroARNs/metabolismo , Traumatismos de los Nervios Periféricos/patología , Fenotipo , ARN Largo no Codificante/metabolismo , Análisis de Secuencia de ARN , Factor de Transcripción AP-1/metabolismo
16.
Dev Cell ; 34(6): 613-20, 2015 Sep 28.
Artículo en Inglés | MEDLINE | ID: mdl-26418293

RESUMEN

It is becoming clear that a radical change of cell identity of differentiated cells in vivo, triggered by injury or other adversity, provides an essential route to recovery for many different mammalian tissues. This process, which we term adaptive cellular reprogramming, promotes regeneration in one of two ways: by providing a transient class of repair cells or by directly replacing cells lost during tissue damage. Controlling adaptive changes in cell fate in vivo in order to promote the body's own cell therapy, particularly by pharmacology rather than genetics, is likely to become an increasingly active area of future work.


Asunto(s)
Diferenciación Celular , Plasticidad de la Célula , Reprogramación Celular/fisiología , Regeneración/fisiología , Cicatrización de Heridas , Animales , Humanos
17.
BMJ Case Rep ; 20122012 Dec 06.
Artículo en Inglés | MEDLINE | ID: mdl-23220825

RESUMEN

The authors report of an 8-year-old girl with non-mosaic Patau syndrome. The median life expectancy of Patau syndrome is 7-10 days, and 90% die in the first year of life. Survival is often attributed to mosaicism and the severity of associated malformations. We delineate the developing phenotype and review the literature discussing potential contributory factors to longevity.


Asunto(s)
Trastornos de los Cromosomas/genética , Longevidad , Trisomía/genética , Niño , Cromosomas Humanos Par 13/genética , Femenino , Humanos , Longevidad/genética , Mosaicismo , Fenotipo , Síndrome de la Trisomía 13
18.
Neuron ; 75(4): 633-47, 2012 Aug 23.
Artículo en Inglés | MEDLINE | ID: mdl-22920255

RESUMEN

The radical response of peripheral nerves to injury (Wallerian degeneration) is the cornerstone of nerve repair. We show that activation of the transcription factor c-Jun in Schwann cells is a global regulator of Wallerian degeneration. c-Jun governs major aspects of the injury response, determines the expression of trophic factors, adhesion molecules, the formation of regeneration tracks and myelin clearance and controls the distinctive regenerative potential of peripheral nerves. A key function of c-Jun is the activation of a repair program in Schwann cells and the creation of a cell specialized to support regeneration. We show that absence of c-Jun results in the formation of a dysfunctional repair cell, striking failure of functional recovery, and neuronal death. We conclude that a single glial transcription factor is essential for restoration of damaged nerves, acting to control the transdifferentiation of myelin and Remak Schwann cells to dedicated repair cells in damaged tissue.


Asunto(s)
Regeneración Nerviosa/fisiología , Proteínas Proto-Oncogénicas c-jun/metabolismo , Células de Schwann/metabolismo , Neuropatía Ciática/patología , Adenoviridae/genética , Análisis de Varianza , Animales , Benzofuranos , Movimiento Celular/genética , Modelos Animales de Enfermedad , Regulación de la Expresión Génica/genética , Vectores Genéticos/fisiología , Macrófagos/metabolismo , Macrófagos/patología , Macrófagos/ultraestructura , Ratones , Ratones Transgénicos , Técnicas Analíticas Microfluídicas , Microscopía Electrónica de Transmisión , Neuronas Motoras/metabolismo , Neuronas Motoras/patología , Neuronas Motoras/ultraestructura , Vaina de Mielina/patología , Vaina de Mielina/ultraestructura , Proteínas Proto-Oncogénicas c-jun/genética , Células de Schwann/patología , Células de Schwann/ultraestructura , Neuropatía Ciática/metabolismo , Neuropatía Ciática/fisiopatología , Neuropatía Ciática/terapia , Médula Espinal/patología
19.
J Cell Biol ; 181(4): 625-37, 2008 May 19.
Artículo en Inglés | MEDLINE | ID: mdl-18490512

RESUMEN

Schwann cell myelination depends on Krox-20/Egr2 and other promyelin transcription factors that are activated by axonal signals and control the generation of myelin-forming cells. Myelin-forming cells remain remarkably plastic and can revert to the immature phenotype, a process which is seen in injured nerves and demyelinating neuropathies. We report that c-Jun is an important regulator of this plasticity. At physiological levels, c-Jun inhibits myelin gene activation by Krox-20 or cyclic adenosine monophosphate. c-Jun also drives myelinating cells back to the immature state in transected nerves in vivo. Enforced c-Jun expression inhibits myelination in cocultures. Furthermore, c-Jun and Krox-20 show a cross-antagonistic functional relationship. c-Jun therefore negatively regulates the myelinating Schwann cell phenotype, representing a signal that functionally stands in opposition to the promyelin transcription factors. Negative regulation of myelination is likely to have significant implications for three areas of Schwann cell biology: the molecular analysis of plasticity, demyelinating pathologies, and the response of peripheral nerves to injury.


Asunto(s)
Vaina de Mielina/metabolismo , Proteínas Proto-Oncogénicas c-jun/metabolismo , Animales , Animales Recién Nacidos , Desdiferenciación Celular/efectos de los fármacos , Técnicas de Cocultivo , AMP Cíclico/farmacología , Proteínas de Unión al ADN/metabolismo , Regulación hacia Abajo/efectos de los fármacos , Proteína 2 de la Respuesta de Crecimiento Precoz/metabolismo , Ganglios Espinales/metabolismo , Ganglios Espinales/patología , Proteínas HMGB/metabolismo , MAP Quinasa Quinasa 7/metabolismo , Ratones , Proteínas de la Mielina/metabolismo , Vaina de Mielina/patología , Factor 6 de Transcripción de Unión a Octámeros/metabolismo , Fosforilación/efectos de los fármacos , Proteínas Proto-Oncogénicas c-jun/genética , Ratas , Factores de Transcripción SOXB1 , Células de Schwann/efectos de los fármacos , Células de Schwann/enzimología , Células de Schwann/patología , Factores de Transcripción/metabolismo , Regulación hacia Arriba/efectos de los fármacos , Degeneración Walleriana/patología
20.
Neurobiol Dis ; 24(1): 159-69, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16872830

RESUMEN

Mutations in the DNA-binding domain of EGR2 are associated with severe autosomal dominant forms of peripheral neuropathy. In this study, we show that one such Egr2 mutant (S382R, D383Y), when expressed in Schwann cells in vitro, is not transcriptionally inactive but retains residual wild-type Egr2 functions, including inhibition of transforming growth factor-beta-induced Schwann cell death and an ability to induce the cytoskeletal protein periaxin. More importantly, this mutant Egr2 has aberrant effects in Schwann cells, enhancing DNA synthesis both in the presence and absence of the putative axonal mitogen, beta-neuregulin 1. This is in stark contrast to wild-type Egr2, which causes withdrawal from the cell cycle. Furthermore, mutant Egr2 upregulates cyclin D1 and reduces levels of the cell cycle inhibitor, p27. These observations add significant new evidence to explain how this mutation leads to congenital hypomyelinating neuropathy in humans.


Asunto(s)
ADN/metabolismo , Proteína 2 de la Respuesta de Crecimiento Precoz/genética , Vaina de Mielina/genética , Enfermedades del Sistema Nervioso/genética , Alelos , Animales , Antimetabolitos , Western Blotting , Bromodesoxiuridina , Muerte Celular/genética , Muerte Celular/fisiología , Proliferación Celular , Supervivencia Celular/fisiología , Proteína 2 de la Respuesta de Crecimiento Precoz/metabolismo , Inmunohistoquímica , Proteínas de la Membrana/biosíntesis , Proteínas de la Membrana/genética , Proteína P0 de la Mielina/genética , Proteínas de Neoplasias/biosíntesis , Proteínas de Neoplasias/genética , Enfermedades del Sistema Nervioso/congénito , Neurregulina-1/genética , Mutación Puntual , Proteínas Proto-Oncogénicas c-jun/biosíntesis , Proteínas Proto-Oncogénicas c-jun/genética , Ratas , Proteínas Represoras/biosíntesis , Proteínas Represoras/genética , Células de Schwann/metabolismo , Transducción de Señal/fisiología , Factor de Crecimiento Transformador beta/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA